Contrave (naltrexone/bupropion) is a prescription drug used for weight loss and long-term weight management in certain adults. The drug is prescribed along with diet ...

Contrave (naltrexone/bupropion) is not safe to take while pregnant or breastfeeding. Certain factors, including the risk of fetal harm, may determine whether you ...

Mild side effects of Contrave include nausea, constipation, and headache. Contrave can also cause serious side effects, though these are rare. Examples include increased blood pressure and mood ...

When you shop through retailer links on our site, we may earn affiliate commissions. 100% of the fees we collect are used to support our nonprofit mission. Learn more. A drug that safely melts the ...

If you've tried the usual weight loss approaches-eating well, moving your body and tracking what you consume-but you're still struggling to reach your goal, you may be considering the increasingly ...

Want relief from constant cravings without the high cost of GLP-1 drugs like Ozempic and Zepbound? Montana grandmother Jen Jodrey, 53, says a surprise alternative—Contrave weight loss ...

Researchers have a gentle warning for patients on the receiving end of 765,000 prescriptions for the weight-loss drug Contrave: The cardiovascular safety of this treatment “remains uncertain,” they ...

Orexigen Therapeutics, Inc. OREX and partner Takeda Pharmaceutical Company Ltd TKPYY received a Paragraph IV certification from Actavis ACT which is looking to gain FDA approval for its generic ...

Orexigen announced data from its COR-Diabetes trial for Contrave (naltrexone sustained release (SR)/bupropion SR) for weight lowering and improved glycemic control in obese patients with type 2 ...

Contrave comes as extended-release oral tablets. It has two active ingredients: naltrexone and bupropion. Naltrexone belongs to a drug class called opioid antagonists, and bupropion belongs to a drug ...

Orexigen Therapeutics, Inc. OREX reported a loss of 14 cents per share in the first quarter of 2015, narrower than the Zacks Consensus Estimate of a loss of 16 cents and the year-ago loss of 23 cents.

San Diego’s Orexigen Therapeutics, maker of a weight-loss drug that had once promised to improve the treatment of obesity, has agreed to sell its assets for $75 million cash. The buyer is Nalpropion ...